Form 4: Y-mAbs Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Michael J. Rossi, President and CEO of Y-mAbs Therapeutics, sold 3,917 shares of common stock on March 7, 2025, to cover tax liabilities associated with vesting restricted stock units.
Summary
- Michael J. Rossi, the President and CEO of Y-mAbs Therapeutics, Inc., reported a transaction involving the sale of company stock.
- On March 7, 2025, Rossi sold 3,917 shares of common stock at a price of $5.2 per share.
- This sale was a non-discretionary transaction to cover tax liabilities related to the vesting and settlement of restricted stock units.
- Following the transaction, Rossi still beneficially owns 137,083 shares of Y-mAbs Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document describes a routine stock sale by the CEO to cover tax obligations. It's a neutral event and doesn't necessarily reflect a positive or negative sentiment towards the company's future prospects.
Industry Context
This is a routine Form 4 filing, which is common when company executives sell shares, especially to cover tax obligations related to stock-based compensation. It doesn't necessarily indicate a negative outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date of stock sale transaction |
| 03/11/2025 | Date of signature by Attorney-in-Fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.